What Alertec (PSYCHOANALEPTICS) Treats: Main Uses and Benefits

The primary role of Alertec is to provide symptomatic support for conditions that disrupt the body's natural sleep-wake cycle, focusing on supporting daytime functional stability. This medication is commonly used to help patients manage Excessive Daytime Sleepiness (EDS) associated with specific diagnosed disorders.

Alertec is generally applied across domains where additional symptomatic support is needed to address chronic drowsiness. It is commonly used to help with symptoms in narcolepsy, residual sleepiness from Obstructive Sleep Apnea (OSA), and Shift Work Sleep Disorder (SWD).

The medication helps address symptom clusters that may become intense or disruptive, such as impaired alertness, mental fog, and difficulty concentrating. Its purpose is to provide supportive relief when symptoms interfere with routine activities.

“A key benefit of this treatment is assisting patients in maintaining functional stability and coping more steadily with the overwhelming urges to sleep during the day.”

Quick Fact: Relief for Excessive Daytime Sleepiness

Alertec is relevant when supportive symptom management is appropriate in clinical settings marked by temporary physiological imbalance. It contributes to easing discomfort during periods of heightened symptoms, which may assist with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus Drug Information on Modafinil

Alertec, which contains modafinil, is a wakefulness-promoting agent primarily indicated for adult patients experiencing excessive sleepiness associated with diagnosed narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSAHS) (as an adjunct to continuous positive airway pressure (CPAP)), or shift work sleep disorder (SWSD).

It is not recommended for use in individuals under the age of 17 for any condition and should not be used to treat routine sleepiness or fatigue.

Contraindications and Cautions

Alertec should not be used by patients with a known hypersensitivity to modafinil or armodafinil, or those who have developed a serious rash (such as Stevens-Johnson syndrome) in the past while taking either medication.

Caution is required, and the use may be contraindicated, in patients with pre-existing or recent cardiovascular conditions, including:

• Uncontrolled moderate to severe hypertension
• Cardiac arrhythmias
• History of left ventricular hypertrophy or certain other structural heart abnormalities.

Patients with a history of psychiatric disorders (e.g., psychosis, mania, depression, anxiety) or substance abuse should be monitored closely. Women using hormonal contraceptives should be aware that Alertec can reduce their effectiveness, necessitating the use of alternative birth control methods.

Interactions with other medicines and products

Clinically Significant Interactions

Alertec's interaction profile is primarily defined by its effects on liver enzymes (Cytochrome P450) and its potential for pharmacodynamic interactions with other agents affecting the central nervous system.

Hormonal Contraceptives

Alertec is documented to reduce the efficacy of steroidal hormonal contraceptives (e.g., oral, injectable, or implantable). This is due to the induction of the CYP3A4 enzyme, which increases the breakdown of the contraceptive steroids. Women using these methods must use alternative, effective non-hormonal barrier contraception during treatment and for a specified period after discontinuation (e.g., two months).

Enzyme Substrates

Mechanism	Interacting Medicine Categories
CYP3A4 Induction (Reduced exposure of co-administered drug)	Substrates with narrow therapeutic indices (e.g., Cyclosporine)
CYP2C19 Inhibition (Increased exposure of co-administered drug)	Substrates like Clomipramine, Phenytoin, Diazepam, Propranolol, Warfarin

Other Interactions

The co-administration of Alertec with Monoamine Oxidase Inhibitors (MAOIs) is not recommended. Caution should be exercised with the concurrent use of other CNS stimulants due to the potential for additive effects. Concomitant use with alcohol is also generally not recommended.

Pharmacological Mechanism

The core action of this drug involves binding to and inhibiting the Dopamine Transporter (DAT), and potentially the Norepinephrine Transporter (NET), on nerve cells. This mechanism prevents the reabsorption (reuptake) of dopamine and norepinephrine, resulting in increased concentrations of these activating messengers in the synaptic space.

Modulating Arousal and Wakefulness Systems

The resulting elevation in central dopamine and norepinephrine levels subsequently increases the activity within major brain systems responsible for arousal, including the Histamine and Orexin (Hypocretin) pathways. This coordinated action increases the activity within the Ascending Arousal System, contributing to the maintenance of vigilance.

Resulting Physiological Effect

The combined influence across these pathways results in a shift in the overall neuronal balance toward excitation. This creates a physiological state of elevated general arousal and increased neural activity in attentional pathways, while influencing the neural circuits that regulate the transition to sleep.

How to Use Alertec (Modafinil)

Standardized instructions for using Alertec, which contains the active substance Modafinil, define the approach to its administration as an oral tablet. This medicine is consistently prescribed as a once-daily dose, though the specific timing of administration varies according to the condition being managed.

The standard strength of the tablet is 200 mg, which constitutes the typical daily dose for adult patients across approved uses. The tablets are intended to be swallowed whole and can be taken with or without food. In some regions, the total daily dose for narcolepsy may alternatively be administered in two divided doses: one in the morning and one at noon.

---

Dosing Schedule

Condition	Standard Adult Dose	Administration Timing
Narcolepsy & OSA	200 mg once daily	Taken in the morning
Shift Work Disorder (SWD)	200 mg once daily	Taken approximately one hour before the work shift

---

Population-Specific Use

General labeling addresses dosage modifications for certain patient groups. Patients diagnosed with severe hepatic impairment use a reduced dosage of 100 mg daily, which is half the standard amount. Similarly, for geriatric patients (those over 65 years of age), a lower starting dose, such as 100 mg daily, is generally recommended. The medicine is not recommended for use in the pediatric population. Standard procedure for a missed dose involves skipping the missed dose and resuming the regular schedule, rather than taking the dose too late in the day. Long-term continuous use is periodically re-evaluated by a prescribing physician.

Research Evidence / Overview of Studies

---

Research on the Combined Components

Research has examined a combination of two components in the drug, exploring their individual and joint activity. Studies explored whether this combination was associated with changes in pain scores and symptom severity. Research into the components included investigations into inflammatory and vascular processes associated with migraine. It is not yet clear whether the combination results in a different effect profile compared to each component used alone.

---

Clinical Trials in Acute Migraine

Research has investigated the drug's use in the context of acute migraine attacks. Trials have generally focused on measuring the difference in pain severity when using the medication compared to a placebo or other agents.

• Efficacy Endpoints: The primary goal of most trials has been to evaluate change in pain scores. Outcomes measured included pain-free status at two hours, time until a measured decrease in pain, and assessment of pain status over 24 hours.
• Dose Response: Multiple studies have evaluated whether different doses of the combination were associated with different rates of change in pain scores.
• Comparison Studies: Studies have compared the time to measured pain decrease for the drug against other agents.

---

Use in Specific Patient Groups

Studies focused on evaluating the drug's activity in participants with moderate to severe pain. Research has also explored whether the drug's activity varies based on certain patient characteristics, such as age, sex, and headache history.

• Headache Frequency: Some studies have reported an association between the combination's use and changes in the frequency and intensity of headache episodes. However, research focused primarily on short-term use during attacks rather than evaluating continuous, long-term administration.
• Safety Profile: Research has included evaluations of the drug’s safety profile. The most commonly reported events observed in the studies included nausea and mild dizziness.
• Timing of Administration: Studies evaluating the timing of drug administration often focused on use at the onset of migraine symptoms.

Common questions about Alertec (PSYCHOANALEPTICS) (FAQ)

Q: What is Alertec (PSYCHOANALEPTICS) used for?

According to the official product information, Alertec is indicated for improving wakefulness in adults who experience excessive daytime sleepiness associated with narcolepsy. It is also used to manage sleepiness in adults with obstructive sleep apnea/hypopnea syndrome (OSAHS) who have not found adequate relief from primary OSAHS treatment, such as continuous positive airway pressure (CPAP).

---

Q: How does Alertec (PSYCHOANALEPTICS) work in the body?

Regulatory documents state that Alertec's precise mechanism of action is not completely known, but it is believed to affect certain chemical messengers in the brain. It is generally understood to increase wakefulness by acting on the central nervous system. Official information notes that this action is different from that of traditional amphetamine-like stimulants.

---

Q: Can Alertec (PSYCHOANALEPTICS) be stopped suddenly?

Regulatory information advises that patients should consult their healthcare professional before making changes to their treatment, including stopping the medication. While the drug is not typically associated with withdrawal symptoms, abruptly stopping it could lead to the return of the original excessive sleepiness. Discontinuation should be managed under the supervision of a healthcare provider, as indicated by official guidance.

---

Q: Is Alertec (PSYCHOANALEPTICS) available over the counter?

Alertec is classified as a prescription-only medicine. This means that a doctor must officially assess a patient's condition and determine that the medicine is appropriate for their specific needs. Regulatory sources confirm that it cannot be obtained without a valid prescription from a licensed professional.

Storage and Handling Requirements

Alertec (modafinil) tablets should be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F).

To maintain the drug's stability, keep the tablets in their original container and protect them from moisture and direct heat and light. Avoid storing the medication in damp areas like a bathroom or near a sink.

Child Access and Disposal

Modafinil is classified as a Schedule IV controlled substance due to its potential for misuse and dependence. It is mandatory to keep it out of the reach of children, ideally in a safe and locked location.

Disposal must be conducted according to specific local, regional, and national requirements for controlled substances. Unused or expired medication should generally be returned to an authorized drug take-back location or a pharmacist for proper disposal, ensuring it is not discharged into drains or water courses.